Capital is flowing back into cell and gene therapy. Phacilitate's latest investment report breaks down where the money went in Q2 2026, from early-stage grants through to landmark acquisitions, and what it signals for the sector's momentum heading into H2.
What's inside:
- A full breakdown of cell and gene therapy investment by funding round, including total capital raised
- The top 5 deals in each sector, from Series A rounds to billion-dollar acquisitions
- The most active investors driving deal activity, ranked by participation
- Commentary on what's fuelling investor confidence and where capital is concentrating
Download the report below
)